Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0040586 (tracheobronchitis)
 449 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A detailed study of a population of dogs with kennel cough was undertaken. Twenty-seven (77 per cent) of a total of 35 dogs had pathological evidence of respiratory disease in the form of tracheobronchitis with, in some animals, exudative pneumonia. A variety of viral and bacterial agents were isolated from the respiratory tract of diseased dogs but Bordetella bronchiseptica and canine parainfluenza virus SV-5 appeared to be the most significant organisms recovered.
Vet Rec 1978 Apr 08
PMID:A study of dogs with kennel cough. 20 6

Eight collie-cross pups, eight weeks old, were inoculated intramuscularly with an aluminum hydroxide adjuvanted preparation of killed Bordetella bronchiseptica; the inoculation was repeated after two weeks. Two weeks after the second inoculation, the vaccinated dogs and a control group of four unvaccinated animals were placed in contact with a group of five pups of similar age which had been experimentally infected with a pathogenic strain of B bronchiseptica by an aerosol method. All four unvaccinated control dogs as well as all five experimentally infected dogs developed a respiratory disease characterised by persistent coughing. Six of the vaccinated dogs remained free from clinical respiratory disease while disease was less severe and of shorter duration in the remaining two than in controls. Only slight changes were found in the lungs of vaccinated animals at necropsy while in the controls there was a severe tracheobronchitis. There was a marked reduction in the numbers of B bronchiseptica isolated from the respiratory tract of vaccinated animals when compared with controls. An aluminium hydroxide adjuvanted vaccine may be of value in controlling naturally occurring canine respiratory disease in which B bronchiseptica is involved.
Vet Rec 1978 Jun 03
PMID:Vaccination against canine bordetellosis: protection from contact challenge. 68 92

Of 36 dogs with a history of chronic coughing or dysponea examined by bronchoscopy, eight were found to have parasitic tracheobronchitis. Oral treatment with the anthelmintic levamisole at a rate of 7.5 mg per kg bodyweight was found to be successful in every case.
Vet Rec 1976 Oct 09
PMID:Use of levamisole in the treatment of parasitic tracheobronchitis in the dog. 98 91

During the autumn of 1988 an outbreak of canine infectious tracheobronchitis, which seemed to be more infectious than usual, occurred throughout Scandinavia. Paired serum samples and bacterial swabs were collected from 52 dogs with clinical signs of infectious tracheobronchitis in three districts of Norway. The results revealed a fourfold or greater rise in the titre of antibodies against canine parainfluenza virus in 79 per cent of the cases, strongly suggesting that the virus was of aetiological importance in the outbreak. Bordetella bronchiseptica was not isolated from the diseased dogs, and they showed no rise in the titres of antibodies against influenza virus, reovirus or adenovirus.
Vet Rec 1990 May 12
PMID:Serological, bacteriological and clinical observations on an outbreak of canine infectious tracheobronchitis in Norway. 216 80

Twelve specific pathogen-free (spf) puppies were vaccinated intranasally with a bivalent, modified live vaccine against infectious tracheobronchitis (group 1) and six puppies of the same age and from the same source served as unvaccinated controls (group 2). Both groups were challenged with wild-type Bordetella bronchiseptica and canine parainfluenza virus by the aerosol route 56 weeks after group 1 had been vaccinated, and at the same time six 10-week-old spf puppies from the same source (group 3) were also challenged. Oronasal swabs were taken regularly before and after the challenge, for the isolation of bacteria and viruses, and the dogs were observed for clinical signs for three weeks after the challenge. The control dogs became culture-positive for B bronchiseptica and canine parainfluenza virus, but the isolation yields from the vaccinated group were significantly lower (P<0.05). The mean clinical scores of the vaccinated group were 61 per cent lower than the scores of group 2 (P=0.009), and 90 per cent lower than the scores of group 3 (P=0.001).
Vet Rec 2005 Jul 02
PMID:Protection of dogs for 13 months against Bordetella bronchiseptica and canine parainfluenza virus with a modified live vaccine. 1599 38

Eight puppies (group 1) were vaccinated once with a bivalent modified-live vaccine against infectious tracheobronchitis by the intranasal route and at the same time with an injectable trivalent vaccine against canine parvovirus, canine distemper virus and canine adenovirus; a second group of eight puppies (group 2) was vaccinated only with the intranasal bivalent vaccine, and a further eight puppies (group 3) were vaccinated only with the injectable trivalent vaccine. Three weeks later they were all challenged with wildtype Bordetella bronchiseptica and canine parainfluenza virus by the aerosol route, and their antibody responses to the five vaccine organisms were determined. Oronasal swabs were taken regularly before and after the challenge for the isolation of bacteria and viruses, and the puppies were observed for clinical signs for three weeks after the challenge. There were no significant differences in the puppies' titres against canine parvovirus, canine distemper virus and canine adenovirus type 2 between the groups vaccinated with or without the bivalent intranasal vaccine. After the challenge the mean clinical scores of the two groups vaccinated with the intranasal vaccine were nearly 90 per cent lower (P=0.001) than the mean score of the group vaccinated with only the trivalent injectable vaccine, and the puppies in this group all became culture-positive for B bronchiseptica and canine parainfluenza virus. There were only small differences between the rates of isolation of B bronchiseptica from groups 1, 2 and 3, but significantly lower yields of canine parainfluenza virus were isolated from groups 1 and 2 than from group 3.
Vet Rec 2007 Jan 13
PMID:Compatibility of a bivalent modified-live vaccine against Bordetella bronchiseptica and CPiV, and a trivalent modified-live vaccine against CPV, CDV and CAV-2. 1722 May 20